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SUMMARY
Individual reports suggest that the central nervous
system (CNS) contains multiple immune cell types
with diverse roles in tissue homeostasis, immune
defense, and neurological diseases. It has been chal-
lenging to map leukocytes across the entire brain,
and in particular in pathology, where phenotypic
changes and influx of blood-derived cells prevent a
clear distinction between reactive leukocyte popula-
tions. Here, we applied high-dimensional single-cell
mass and fluorescence cytometry, in parallel with ge-
netic fate mapping systems, to identify, locate, and
characterize multiple distinct immune populations
within the mammalian CNS. Using this approach,
we revealed that microglia, several subsets of
border-associated macrophages and dendritic
cells coexist in the CNS at steady state and
exhibit disease-specific transformations in the im-
mune microenvironment during aging and in models
of Alzheimer’s disease and multiple sclerosis.
Together, these data and the described framework
provide a resource for the study of disease mecha-
nisms, potential biomarkers, and therapeutic targets
in CNS disease.
INTRODUCTION
The central nervous system (CNS) was long regarded as a site of
limited immune surveillance due to the lack of obvious lymphatic
vessels, the blood brain barrier (BBB), and slow transplant rejec-
tion (Murphy and Sturm, 1923; Shirai, 1921). However, the CNS
is a compartmentalized organ comprising the parenchyma, the
ventricles containing the choroid plexus and cerebrospinal fluid
(CSF), the meningeal layers that envelop the parenchyma, and
several ‘‘absolute’’ (BBB) and semi-permeable barriers (blood-
CSF, blood-leptomeningeal) (Shechter et al., 2013). It is now
clear that the level of steady-state immune privilege varies
dramatically between compartments.
The parenchyma appears to be the most immune-privileged
compartment within the CNS, and in the steady state the only
resident leukocytes are microglia: specialized macrophages
that are seeded into the brain during embryogenesis (Ginhoux
et al., 2010; Schulz et al., 2012), where they contribute to
neuronal synapse sculpting and immune surveillance (Colonna
and Butovsky, 2017; Prinz and Priller, 2014; Salter and Beggs,
2014). Outside the parenchyma, immune surveillance is medi-
ated by bone-marrow-derived dendritic cells (DCs) (Greter
et al., 2005; Kivis€akk et al., 2009) and CNS border-associated
macrophages (BAMs), which line the meninges, choroid plexus,
and perivascular spaces (Bechmann et al., 2001) and have
recently been shown to also be embryonically derived (Gold-
mann et al., 2016).
During neuro-inflammation, the immune landscape of the CNS
changes dramatically; resident immune cells become activated
and the parenchyma can be infiltrated by inflammatory leuko-
cytes from the periphery. CNS-resident phagocytes must pre-
sent cognate self-antigen to encephalitogenic T cells during
the course of experimental autoimmune encephalomyelitis
(EAE), a murine model of multiple sclerosis (MS) (Schreiner
et al., 2009). Several studies assign this role either to DCs or
BAMs during the initiation of EAE (Greter et al., 2005; Kivis€akk
et al., 2009; Schl€ager et al., 2016). Also, during aging, inflamma-
tion in the brain gradually increases, a process termed ‘‘inflam-
maging’’ (Deleidi et al., 2015), and CNS leukocytes may also
play a role in age-related inflammation and neurodegeneration
(Baruch et al., 2013; Prokop et al., 2015; Ritzel et al., 2016).
Despite the importance of CNS-resident leukocytes in these
disease processes, our ability to fully characterize these popula-
tions and to understand their distinct functions has so far been
limited: at present, reliable discrimination of microglia and
BAMs (both express low levels of CD45 compared to other
leukocytes) can be achieved within tissue sections only by
immunohistochemistry methods, where their distinct patterns
of localization (parenchyma versus CNS border regions) provide
a surrogate for their identification (Goldmann et al., 2016).
Moreover, a clear distinction between BAMs and DCs within
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cohabited CNS compartments remains challenging. This prob-
lem is compounded by the phenotypic changes that occur
during various CNS pathologies. For instance, during neuroin-
flammation, the invasion by peripheral leukocytes makes it virtu-
ally impossible to unambiguously discriminate blood-derived
leukocytes from tissue-resident populations (Greter et al., 2015).
Here, we describe an approach that overcomes many previ-
ous localization- and imaging-dependent limitations to identify
and characterize immune cells within the murine CNS. We
created a high-dimensional single-cell proteome atlas of
immune populations using high parametric mass cytometry
(Bandura et al., 2009; Becher et al., 2014) combinedwith location
information from immunohistochemistry (IHC) and verified by
22-color fluorescence cytometry and reporter and fate-mapping
systems. We uncovered the existence of cellular subsets within
CNS-resident phagocyte populations at steady state and further
defined the entire immune landscape during aging, neurodegen-
eration, and neuroinflammation, highlighting the differences and
similarities between these different forms of CNS pathology. This
comprehensive immune cell atlas of the mammalian CNS will
enable the study of individual leukocyte populations and their
roles in CNS development, homeostasis, and disease.
RESULTS
The Steady-State CNS Contains Diverse Resident
Immune Cell Populations
We employed an integrated set of strategies to enable mapping
of the immune cell populations within the murine CNS, as shown
in Figure 1A. To capture the complexity of cellular phenotypes,
we designed a 43-heavy metal isotope-tagged surface antibody
panel for mass cytometry (Table S1). Mass cytometry data were
further complemented by 22-color fluorescence cytometry, and
the location of specific cell populations within the CNS was
analyzed by IHC.
We first interrogated the steady-state CNS in 8-week-old
C57BL/6 mice. To give an overview of all immune populations
present, mass cytometry data was visualized in a t-SNE map
and cells categorized by FlowSOM-guided clustering (Figures
1B, 1C, and S1A; Hartmann et al., 2016). This approach revealed
a substantial amount of complexity of leukocytes within the
normal CNS: microglia and other macrophage-like cells, several
types of monocytes (Ly6Chi and Ly6Clo monocytes and mono-
cyte-derived cells [MdCs]), as well as classical DCs (cDCs),
plasmacytoid DCs (pDCs), B cells (CD24+ and CD24, see
Figure S1A), T cells, natural killer (NK) cells, NKT cells,
innate lymphoid cells (ILCs), eosinophils, and mast cells. Tradi-
tional manual gating of the mass cytometry data confirmed the
identity of these cell populations (Figure S1B). Microglia
(CD45loCD11bloF4/80+CD64+MeTK+Cx3CR1hiSiglec-H+CD88lo)
were the most abundant immune cells in the steady-state CNS
(Figure 1D). We were also able to identify a separate population
of cells with a closely related surface protein expression pattern
(CD45lo/+CD11bloF4/80hiCD64hiMeTK+Cx3CR1+CD88hi); how-
ever, these cells lacked typical microglial Siglec-H expression
and instead expressed CD206 and CD38 (Figures 1C and S1A).
Using IHC, Goldmann et al. (2016) recently described a popu-
lation of embryonically derived macrophages with a microglia-
like phenotype that occupy distinct locations, namely the border
regions of the CNS in contrast to the parenchyma where only
microglia reside. We hypothesized that the non-microglia
macrophage-like cells identified in our unbiased analysis were
in fact BAMs. These BAMs are virtually indistinguishable from
microglia using conventional (CD45 versus CD11b) gating strate-
gies (Figure S1B).
To confirm this and the identities of the other cell populations
present, we first used functional assays that exploit character-
istic cell type-restricted responses to different stimuli. We
treated mice with either an antagonistic colony-stimulating
factor 1 receptor) (CSF1R) antibody to deplete tissue-resident
macrophages and Ly6Clo monocytes, but not microglia (which
are likely protected by the BBB) or Ly6Chi monocytes (Hoeffel
et al., 2015), or with the recombinant growth factor Flt3L, which
specifically expands DCs (Maraskovsky et al., 1996; Anandasa-
bapathy et al., 2011). Indeed, anti-CSF1R treatment depleted the
cells we identified as BAMs and Ly6Clo monocytes but had no
effect on other cell types (Figure 1E). The depletion of BAMs
further confirms their location within the border regions of the
CNS where the vasculature has different barrier properties to
the BBB of the parenchymal vasculature (Engelhardt et al.,
2017). Flt3L treatment in turn increased the frequency of DCs,
as well as Ly6Chi monocytes and MdCs (after 9 days of treat-
ment, the bone-marrow monocyte progenitors are also tar-
geted), while having no effect on microglial, BAM, or Ly6Clo
monocyte populations (Figure 1E), thus functionally confirming
our algorithm-guided population identification.
To determine whether the leukocytes we detected in the CNS
were within the tissue itself or within the lumen of vessels or
capillaries, we intravenously injected fluorescently (PE)-labeled
anti-CD45 antibodies (Anderson et al., 2014). More than 98%
of control blood leukocytes were labeled with anti-CD45-PE,
while only 5% of CNS leukocytes were labeled (Figures
S2A–S2C); thus 95% of all CNS leukocytes identified are bona
fide extra-vascular CNS-resident cells. Neutrophils constituted
the third largest leukocyte population in the CNS, 81.8% ±
3.0% being unlabeled and therefore tissue resident (Figures
S2D and S2E). Tissue sections revealed neutrophils predomi-
nantly within the dura mater (Figure S2F), as well as the pia mater
and the ependyma (data not shown) of the steady-state CNS.
Together, our analysis of the steady-state CNS revealed multiple
immune cell populations residing within CNS compartments,
including a subset of microglia-like BAMs.
BAMs Are CNS-Resident Macrophages that Are Distinct
from Microglia
We used our mass cytometry data to design a 22-color antibody
panel for fluorescence cytometry (Table S1) that identified all the
major leukocytes in the CNS. This allowed us to use genetic re-
porter and fate-mapping experiments aimed at determining the
relationshipbetweenBAMs,microglia, andCNSDCs.Tocompare
the mass and fluorescence cytometry datasets and their ability to
identify the same cell populations, we employed force-directed
analysis to generate a Scaffold map (Spitzer et al., 2015): we first
modeled a reference map of CNS leukocytes from our mass
cytometry data, using manually gated populations as landmark
nodes (in colors) and the initial 100 FlowSOM nodes (before
metaclustering) as unsupervised nodes (in gray) (Figure 2A).
Mapping the flowcytometry data onto thismasscytometry-based
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Figure 1. Mass Cytometry Identifies CNS-Associated Leukocyte Diversity in the Steady-State
For a Figure360 author presentation of Figure 1, see the figure legend at http://dx.doi.org/10.1016/j.immuni.2018.01.011.
(A) Schematic representation of the experimental approach.
(B) t-SNE map displaying 100,000 randomly sampled cells from the CNS of steady-state 2-month-old C57BL/6 mice analyzed by mass cytometry. Colors
correspond to FlowSOM-guided clustering of cell populations (n = 3, representative of 6 independent experiments).
(C) Median marker expression values for each population.
(D) Frequencies of steady-state CNS leukocytes.
(E) Experimental schematic (left) and frequencies (right) of myeloid populations within total CNS leukocytes after indicated treatments (n = 3).
See also Figures S1 and S2 and Table S1. Error bars represent range.
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reference map showed that cells within unsupervised nodes that
groupedaround the landmarknodeshad theexpectedexpression
profiles and were present at similar frequencies to those in the
original reference map (Figures 2B and 2C).
We then examined cells from the CNS of Sall1GFP reporter
mice. Sall1 is a transcription factor expressed by microglia in
adult mice, and in Sall1GFP mice the green fluorescent protein
(GFP) is produced along with real-time expression of Sall1 (Butt-
gereit et al., 2016). We found that GFP expression in Sall1GFP
mice was exclusive to microglia, and Sall1 did not label BAMs
or cDCs (Figures 2D and 2E and as a clustered t-SNE in Fig-
ure S3A). Thus, in addition to the phenotypic distinctions be-
tween BAMs and microglia revealed by mass cytometry, we
confirmed Sall1 as a key transcription factor, which can be
used to distinguish these closely related cell populations and
further confirmed that our cluster assignment of microglia and
BAMs as separate populations was correct.
Microglia and the majority of BAMs are long lived (Goldmann
et al., 2016) while DCs are bone-marrow derived and short lived
(Merad and Manz, 2009). To utilize this difference in longevity for
the identification of myeloid cell populations within the CNS, we
used Cx3cr1CreER Rosa26-RFP inducible fate-map mice where
tamoxifen induces irreversible expression of red fluorescent pro-
tein (RFP) in CX3CR1+ cells (Yona et al., 2013). Short-lived
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Figure 2. Microglia and BAMs Are Distinguished by Genetic Targeting
(A) A Scaffold reference map of the steady-state adult CNS leukocyte landscape constructed from mass cytometry data displaying 100 unsupervised FlowSOM
nodes and manually gated landmark nodes.
(B) Fluorescence cytometry data of steady-state adult CNS leukocytes mapped onto the reference map created in (A).
(C) Representative fluorescent marker expression in the Scaffold map.
(D) CD45+ CNS leukocytes (left) and frequency of GFP+ cells (right) in Sall1GFP+/ reporter mice (n = 3, representative of two independent experiments).
(E) GFP expression overlaid onto the Sall1GFP+/ Scaffold map.
(F) CD45+ CNS leukocytes (left) and frequency of RFP+ cells (right) in Cx3cr1CreER Rosa26-RFP mice 5 weeks after tamoxifen treatment. (n = 5, showing 4 pooled
experiments).
(G) RFP expression overlaid onto the Cx3cr1CreER Rosa26-RFP Scaffold map.
See also Figure S3. Error bars represent range.
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labeled cells will be replaced from unlabeled bone marrow pro-
genitors, while long-lived or self-renewing cells will remain
RFP+. Here, 5 weeks after tamoxifen treatment of adult
Cx3cr1CreER Rosa26-RFP mice, less than 5% of monocytes
were RFP+ (Figure S3B), while almost 80% of microglia, 50%
of BAMs, and less than 10% of DCs were RFP+ (Figures 2F
and 2G). Most BAMs retained the RFP label, as a result of the
earlier tamoxifen treatment, whereas most DCs lost RFP expres-
sion. Hence, we concluded that CX3CR1+ BAMs are replaced
more slowly than CX3CR1+ DCs. This differential longevity
combined with the lack of Sall1 expression by non-microglial
cells confirms that the high-dimensional map produced here cor-
responds to the predicted ontogeny of CNS leukocytes.
Specific BAM Subsets Are Enriched in Distinct CNS
Compartments
Now that we could reliably discriminate BAMs from microglia
and DCs, we conducted an in-depth BAM phenotype analysis.
This revealed expression of the macrophage-associated
markers MerTK, CD64, and F4/80, as well as CD16/32 (Fig-
ure 3A), and absence of the DC, monocyte, and microglia
markers CD11c, Ly6C, and Siglec-H, respectively. Further, we
identified four BAM subsets based on differential expression of
CD38, MHCII, and CCR2: subset 1 (CD38+MHCIICCR2), sub-
set 2 (CD38+MHCII+CCR2), subset 3 (CD38MHCII+CCR2),
and subset 4 (CD38MHCII+CCR2+) (Figures 3B and 3C). The
median expression values of each marker in the different BAM
subsets are compared in a heatmap (Figure 3D). The majority
of BAMs (75.7% ± 1.2%) were situated within subset 1, while
subsets 2, 3, and 4 comprised 7.6% ± 0.8%, 7.2% ± 0.2%,
and 9.4% ± 1.2% of total BAMs, respectively (Figure 3E). Sub-
sets 3 and 4 were almost identical but differed in the amount of
CCR2, CD44, and CD206. To understand the full heterogeneity
and distinct high-dimensional phenotypes of the four BAM
subsets at the single-cell level, we employed categorical One-
SENSE analysis (Cheng et al., 2016), where the y axis represents
the lineage profile, the x axis represents an activation marker
profile (Figure 3F), and co-regulation of marker expression is
also shown, e.g., CD206 expression was high on subset 1 but
decreased as the activation markers MHCII and CD44 increased
toward subsets 2, 3, and 4 while high expression of other macro-
phage markers like CD64 was maintained.
We then used confocal microscopy to ask whether these
subsets are enriched in specific compartments of the CNS. The
available anti-mouse CD38 performed poorly in IHC, but using
fluorescence cytometry we found that Lyve1 and CD38 expres-
sion closely overlapped (Figures 3G and S4A) and therefore that
Lyve1 was a suitable surrogate for CD38 on BAMs. As lymphatic
vessels also express Lyve1 and are present in the dura mater
(Louveau et al., 2015), we also stained for collagen IV, which is
expressed on vessels but not BAMs. Combining Lyve1 or MHCII
with the macrophage marker Iba-1, we located BAMs within the
pia mater, perivascular space, choroid plexus, and dura mater
and showed that they express CD206, as previously shown (Fig-
ure S4B; Goldmann et al., 2016). By histology, we identified three
BAM subsets in these regions using differential Lyve1 andMHCII
expression (Figure S4C). The initial CyTOF-identified subsets 3
and 4 are merged here. Of note, Lyve1+MHCII+ (subset 2) BAMs
were enriched in the pia mater and perivascular space, whereas
the dura mater harbored relatively more single-positive MHCII+
BAMs (subsets 3 and4) and fewLyve1+MHCII+BAMs (Figure 3H).
The choroid plexus contained a similar frequency of each of the
three BAM subsets. Single-positive Lyve1+ BAMs (subset 1)
were present in all locations. Only MHCII+ BAMs, enriched in the
choroid plexus and dura mater, expressed CCR2+ (Figure 3B)
(subset 4), consistent with their proposed high turnover rate and
replacement by CCR2+ bone marrow-derived cells within the
choroid plexus (Goldmann et al., 2016). Together, these data
showed that BAMs are heterogeneous macrophages that can
be divided into subsets based on their distinct expression of
CD38 and MHCII and are specifically enriched in different CNS
compartments. The phenotypic variations of BAMs across the
CNS may reflect functional differences and could be shaped by
cues from their specific local microenvironments.
Heterogeneous Subsets of DCs Exist in the CNS
In addition to BAMs, DCs also localize in the CNS border regions
and are considered to be the prime antigen-presenting cells
(APCs) at these sites (Anandasabapathy et al., 2011; Greter
et al., 2005). In other tissues, DCs exist as functionally and pheno-
typically distinct subsets but little is known of the DCs associated
with the CNS. We used our mass cytometry datasets to perform
an in-depth phenotypic characterization of CNS-associated DCs
(Figure 4A). We identified three main DC subsets corresponding
to cDC1s, cDC2s, and pDCs (Figure 4B), differentiated by
their expression of CD11b (or CD172) and CD24 (Figure 4C). In
addition, Ly6C, B220, or Siglec-H confirmed the pDC identity of
subset 6. The cDC2 population was heterogeneous and could
be further separated into CD24+CD206+ cDC2 (subset 1),
CD24CD64+/loCD206/lo cDC2 (subset 2), CD135hi cDC2
(subset 3), and PDL1+ cDC2 (subset 4), while cDC1s (subset 5)
were CD11bloCD172loCD24+CD135hiCD117+ (Figure 4D). As in
most other organs (Guilliams et al., 2016), cDC2s were relatively
more abundant than cDC1s (Figure 4E). The lineage markers
and activation profiles of these subsets were again fully
revealed using categorical One-SENE (Figure 4F). We localized
Figure 3. BAMs Exist as Phenotypically Distinct Subsets Enriched in Specific CNS Compartments
(A) CNS BAMs were plotted onto a separate t-SNE. Outlined plots represent four distinguishing markers of BAM subsets.
(B) BAMs clustered into four subsets based on the entire panel of markers.
(C) Expression of CD38, MHCII, CCR2, and CD206 by the four BAM subsets (colored).
(D) Relative frequencies of the four BAM subsets across 3 mice (n = 3, representative of 4 independent experiments).
(E) Median expression of mass cytometry markers on each BAM subset and microglia.
(F) One-SENSE analysis of BAMs along lineage and activation profiles.
(G) Fluorescence cytometry data depicting expression of Lyve1, CD38, and MHCII in three BAM subsets.
(H) Density of BAM subset occurrence within each region of interest (ROI) (nR 5 mice, ROIR 4 per mouse).
See also Figure S4. Error bars represent the median ± SEM.
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CD11c+MHCII+ DCs of the CNS by confocal microscopy only
in the choroid plexus, pia mater, and dura mater, and not in
the perivascular space (Figure 4G), suggesting that these
DC-enriched compartments may serve as entry sites for MHC-
dependent T cells.
As we have shown that CNS cDC2s exist with some heteroge-
neity in their surface phenotype, we sought to confirm their
inherent identity compared to cDC1s. Both cDC2s and cDC1s
expanded to a similar extent with Flt3L treatment (Figure 4H)
and moreover cDC1s were IRF8hiIRF4int and cDC2s were
IRF8IRF4hi (Figure 4I), as previously predicted (Guilliams
et al., 2016). The apparent heterogeneity of cDC2s has also
been noted at other organs such as the lung (Schlitzer et al.,
2013) and heart (Clemente-Casares et al., 2017). Thus, our
mass cytometry analysis of CNS-associated DCs revealed the
presence of the three main DC subsets also represented in other
organs of the body. This strengthens the notion that also in the
CNS, DCs are the prime APCs among all resident leukocytes
and vital for the homeostatic immune surveillance of the CNS.
Aging and Neurodegenerative Disease Change the CNS
Immune Cell Landscape
Aging has profound effects on the entire CNS landscape. We
therefore asked how the immune cell populations in the CNS
changed in aged mice by comparing geriatric mice aged 1.5
years with younger adult mice aged 2 months. We first noted a
substantial increase in the frequency of T cells from 1.5% ±
0.9% in adult mice to 11.1% ± 4.2% in geriatric mice, while
NKT cells and pDCs were significantly less frequent in geriatric
mice (p = 0.028 and 0.029, respectively) (Figures 5A and 5B).
We also observed an increased frequency of CD38+MHCII+
CCR2 and CD38MHCII+CCR2 BAMs and a corresponding
decrease in CD38+MHCIICCR2 and CD38MHCII+CCR2+
BAMs in geriatric mice (Figure 5C); alongside, the frequency of
CD24+ cDC2s decreased, while CD135+ cDC2s were more
abundant in geriatric mice (Figure 5D).
We found a phenotypic signature in a subset of microglia in
geriatric mice which expressed high levels of CD11c and CD14
(Figure 5E). Aging is a major risk factor for neurodegenerative
diseases, and changes in microglial morphology precede pa-
thology in Alzheimer’s patients (Perry and Holmes, 2014; Streit
et al., 2009). We therefore asked whether the age-related
changes in leukocyte populations and the age-associated mi-
croglial phenotype in particular were present in a murine model
of Alzheimer’s disease (AD). We compared the plaque-harboring
cortex with the non-plaque-harboring cerebellum (internal con-
trol) of 4-month-old APP/PS1 mice (Radde et al., 2006; Vom
Berg et al., 2012), and age-matched WT littermates (external
control). We found that, as in much older geriatric mice, the
frequency of T cells was increased in the plaque-harboring cor-
tex of AD-prone mice (Figure S3A); while, in contrast to geriatric
mice, the subset distribution of BAMswas unaltered in AD-prone
mice (Figure S3B), suggesting it to be a phenomenon observed
during normal aging.
We also detected a phenotypic signature in a subset of micro-
glia in AD-prone mice that resembled microglia in geriatric mice
in the expression of CD11c and CD14 (among other markers,
data not shown), and which was absent in WT littermate controls
(Figure 5F). Approximately 11.9% ± 6.5% of microglia had this
signature in geriatric mice, compared to virtually zero in young
adult mice, and approximately 13.2% ± 1.7% in the plaque-
bearing cortex of AD-prone mice, while these cells were almost
undetectable in the unaffected cerebellum and in WT littermate
cortex or cerebellum (Figures 5G and S3C). A similar subset of
microglia was also described by Keren-Shaul et al. (2017) by
sc-RNaseq in 5XFAD mice. We located these CD11c+ microglia
around Ab plaques in APP/PS1mice (Figure S3D). The full signa-
ture of these reactive microglia compared to non-reactive micro-
glia in geriatric mice (fold change) shows that, in addition to
increased phagocytosis-associated markers CD11c and CD14,
there was an accompanying increase in activation markers
CD86 and CD44 and the inhibitory ligand PDL1 (Figure 5H).
MHCII expression increased slightly while expression of micro-
glial homeostatic checkpoint markers CX3CR1, MerTK, and
Siglec-H decreased. This phenotypic change within the small
age- and AD-associated subset represents a switch from a
homeostatic microglial program to a ‘‘reactive’’ signature that
displays an activated, phagocytic profile (Hanisch and Ketten-
mann, 2007; Krasemann et al., 2017).
Autoimmune-Neuroinflammation Results in Leukocyte
Invasion and Global Changes in the CNS Immune
Landscape
We induced EAE in adult C57BL/6 mice and compared the
immune cellular composition of the CNS at the peak of disease
with steady-state control mice (Figures 6A and S6A). Analyzing
the frequencies (Figures 6B and S6C) and cell numbers (Fig-
ure S6C) of CNS leukocytes, we found that the majority of infil-
trating cells were MdCs, followed by T cells.
Microglia were highly reactive during EAE and exhibited a
markedly different phenotypic signature than in the steady state,
as evidenced by their change in localization on the t-SNE map
(Figure 6A). The microglial identity of these highly reactive
cells during EAE was confirmed in Sall1GFP reporter mice (Fig-
ures 6C and S6D). We then conducted an in-depth analysis
of the phenotypic changes in microglia in response to EAE
Figure 4. Dendritic Cells in the Steady-State CNS Exist as Three Main Subsets
(A) CNS DCs were plotted onto a separate t-SNE. Selected plots represent four chosen distinguishing markers.
(B) DCs clustered into three major subsets based on the entire panel of markers.
(C) Expression of distinguishing markers by the DC subsets.
(D) Relative abundance of the DC subsets within total CNS DCs across 3 mice (n = 3, representative of at least 3 experiments).
(E) Median expression of mass cytometry panel markers on each DC subset.
(F) One-SENSE analysis of DCs by their lineage and activation profiles.
(G) Representative fluorescence immunohistochemistry images of DCs in the pia mater, choroid plexus, and dura mater (nR 2 mice,R 3 sections per mouse).
(H) cDC1 and cDC2 response to the indicated stimuli.
(I) IRF4 and IRF8 expression by cDC1s and cDC2s.
Error bars represent range.
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inflammation: once again, expression of microglial homeostatic
checkpoint markers CX3CR1, MerTK, and Siglec-H was
reduced, and expression of markers CD44, CD86, PDL1, and
CD11c increased, as similarly observed in geriatric mice. How-
ever, in contrast to age- and AD-associated microglia, CD14
expression decreased during EAE and an increase in MHCII
and Sca-1 was observed (Figures 6D, 6E, and S6E). The conver-
sion from the homeostatic microglial signature to a highly reac-
tive state signature was also evident when comparing lineage
and activation profiles using categorical One-SENSE (Figure 6F).
Here and in the t-SNE map (Figures 6A and S6E), there are very
few EAE microglia that are located in the same area as steady-
state microglia. This is because of a shift in both the lineage
and activation profiles of the entire microglia population. Of
note, this phenotypic change affects the entire microglial popu-
lation homogeneously, which is in stark contrast to the small
subset of reactive microglia in aging and neurodegenerative
disease.
BAMs, MdCs, and DCs share a number of lineage markers.
Interrogating their profiles more closely in EAE, we found that
MdCs, monocytes, and cDCs were more similar to each other
while BAMs and pDCs were distinctly separated on the t-SNE
map (Figure S7A). We used Cx3cr1CreER Rosa26-RFP EAE
mice to validate that BAMs and MdCs were indeed identified
correctly. At peak EAE, as in steady state, only microglia and
BAMs were RFP+ (Figures 7A and S7B). However, the number
of total and RFP+ BAMs decreased during EAE relative to steady
state and BAMs became outnumbered by infiltrating MdCs (Fig-
ures 7B and S6C). As with microglia, the phenotype of all BAMs
was altered in EAE (Figure 7C): inflammation led to increased
expression of MHCII and the activation markers CD44 and
Sca-1, as well as PDL1, CD117, and CD11c (Figure 7D).
Ly6Chi monocytes invade the CNS parenchyma and differen-
tiate into inflammatory and pathogenic MdCs during EAE
(Codarri et al., 2013; Croxford et al., 2015a, 2015b; Yamasaki
et al., 2014). This differentiation program is supported by our
data as Ly6Chi monocytes did not yet undergo inflammation-
induced phenotypic changes (Figure S7A), while MdCs were
highly activated, expressing Sca-1, MHCII, PDL1, CD11a,
CD86, CD38, CD14, and CD16/32 and a macrophage-like line-
age profile (Figure 7E). This profile has previously rendered
them hard to distinguish from microglia and BAMs. We also
distinguished cDC subsets and pDCs and show their lineage
and activation profiles during peak EAE (Figure 7F).
Finally, we defined a myeloid panel of 12 markers within our
mass cytometry data to clearly discern reactive microglia,
BAMs, MdCs, and cDCs even in the inflamed CNS (Figure 7G).
Together, our analysis shows that CNS-resident myeloid cells
become highly activated during neuroinflammation but can still
be distinguished frommacrophage-like invadingMdCs, confirm-
ing the utility of our high-dimensional myeloid immune atlas as a
valuable resource for marker combinations allowing mapping of
cellular subsets in downstream analyses.
DISCUSSION
We have systematically characterized the leukocyte landscape
within the mammalian CNS under a range of conditions. While
lymphocyte populations can be readily identified via expression
of unique canonical antigens, and recent reports have begun to
characterize them in the steady-state CNS (Korin et al., 2017),
CNS myeloid cells have proven highly challenging to study.
The CNS myeloid compartment is the largest CNS-resident
immune cell population and has been implicated in multiple as-
pects of CNS health and disease, including MS, AD, dementia,
and Parkinson’s disease, as well as psychiatric diseases and
behavioral disorders like schizophrenia, autism, and depression
(Herz et al., 2017; Kettenmann et al., 2013; Prinz and Priller,
2014). Using high-dimensional cytometry in combination with
neural-network based algorithms, we identified microglia,
BAMs, DCs, and monocytes as separate populations by exten-
sive surface protein phenotyping. These data were corroborated
by functional, genetic, and fate-mapping approaches.
Interrogating these cells in the high-dimensional space led us
to uncover four previously uncharacterized BAM subsets, distin-
guished by differential expression of CD38 or Lyve1, MHCII, and
CCR2. It is likely that the CCR2+ subset (subset 4) represents a
fresh hematopoietic myeloid cell to replace the BAMs that accu-
mulate in the choroid plexus (Goldmann et al., 2016) and dura
mater. We showed that single-positive CD38+ or Lyve1+ BAMs
made up approximately 30% of pial BAMs and that they can
be CX3CR1lo/. Thus this BAM subset may not be efficiently tar-
geted by the commonly used Cx3CR1CreER Rosa26 fate-map
system. On the other hand, MHCII+ BAM subsets expressed
high levels of CX3CR1 and were therefore likely targeted better
in this system. The dura mater distinctly lacked Lyve1+MHCII+
BAMs, but these BAMs were enriched in the pia mater, perivas-
cular space, and choroid plexus. The dura mater harbored
predominantly Lyve1MHCII+ BAMs. The function of the pheno-
typically different dural BAMs in CNS homeostasis and disease
likely differs from pial, perivascular, and choroid plexus BAMs
as the dura is not in physical contact with the brain and encloses
a lymphatic system (Aspelund et al., 2015; Louveau et al., 2015).
With our surface protein profile of BAMs, it is now possible to pu-
rify their subsets for detailed study into their potential roles in,
e.g., vascular maintenance, immune suppression, or activation.
Figure 5. Aging Causes an Altered CNS Immune Landscape and a Subset of Reactive Microglia Emerges
(A) Non-microglial CNS leukocytes from adult (2-month-old) and geriatric (1.5-year-old) C57BL/6 mice analyzed by mass cytometry.
(B–D) Frequencies of (B) non-microglial CNS leukocytes, (C) BAM, and (D) cDC subset distributions in adult and geriatric mice.
(E) Normal and reactive microglia differentiated by CD14 and CD11c expression in adult and geriatric mice (n = 3).
(F) Normal and reactive microglia in 4-month-old WT and APP/PS1 mice (n = 2–4, experiment repeated twice).
(G) Frequencies of age- or AD-associated microglia in adult versus geriatric C57BL/6 mice, or the cortex (plaque-harboring) and cerebellum (internal control) of
WT versus APP/PS1 mice, respectively.
(H) Fold change (log10) in expression of myeloid markers in the mass cytometry panel between normal and reactive microglia in geriatric mice.
**p value significant (< 0.05) with a Benjamini-Hochberg (BH) false discovery rate (FDR) < 5%. Error bars represent range except in (H) where error bars represent
the median ± SEM. See also Figure S5.
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Figure 6. Neuroinflammation Is Accompanied by CNS Invasion and Homogeneous Microglial Activation
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BesidesBAMs,wewere also able to discernmultiple subsets of
DCswithin thesteady-stateCNS.Futurestudiesshoulddetermine
which of the identifiedCNSDCsubsets sampleCNSantigens and
migrate to the draining cervical lymph nodes to activate naive
T cells or Treg cells to maintain immune suppression. This is rele-
vantduringhomeostasis,CNS infections, andneurodegeneration,
where self, foreign, or pathogenic proteinsmay accumulatewithin
the CNS parenchyma and meninges (Kalaria et al., 1996).
We extended our analysis to pathologic processes of aging
and neurodegenerative disease. We identified a specific subset
of reactive microglia associated with aging and AD. As we
observed this microglial phenotype in geriatric WT mice and in
relatively young APP/PS1 mice, this indicates that it may arise
due to a specific response to cues from the local microenviron-
ment rather than from cell-intrinsic aging. These cues may be
similar in geriatric and APP/PS1 mice, e.g., myelin fragmentation
(Safaiyan et al., 2016), protein accumulation (David, 2012), neuro-
degeneration (Krasemann et al., 2017; Wyss-Coray, 2016), and/
or increased inflammatory mediators (Deleidi et al., 2015; Hepp-
ner et al., 2015). This is particularly supported by the increase in
CD14 expression as CD14 is the co-receptor to the toll-like re-
ceptor 4 (TLR4) and together these receptors can be activated
by amyloid-b (Reed-Geaghan et al., 2009) and upregulated by in-
flammatory cytokines like TNF-a (Zanoni et al., 2011). A recent
report using sc-RNaseq of microglia showed that disease-asso-
ciated microglia appear with disease progression in 5XFAD mice
and have a phagocytic transcriptome signature (Keren-Shaul
et al., 2017). However, regulation of mRNA and the encoded pro-
tein can differ dramatically and sc-RNaseqwill, depending on the
analysis depth, detect only abundant transcripts (Peterson et al.,
2017). In support of this notion, many of the proteins we and
others use to describe the CNS immune landscape did
not overlap with the public sc-RNaseq data (https://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSE98969) (Keren-Shaul
et al., 2017). Thus, our analysis provides surface proteinmarkers,
which can be targeted with commercially available mAbs,
enabling cell isolation for further studies.
In contrast to neurodegenerative diseases, neuroinflammation
is accompanied by a massive influx of immune infiltrates and
dramatic changes in the CNS landscape. A recent report (Korin
et al., 2017) suggested that all cells that are CD45hi in the
steady-state CNS are ‘‘CNS infiltrates.’’ However, leukocytes
in the steady-state CNS do not necessarily need to be immi-
grants. CNS infiltration into the parenchyma is a hallmark of
neuro-inflammation (Becher et al., 2017). Furthermore, Korin
et al. (2017) state that CD44 is a marker that distinguishes
CNS-infiltrating cells from CNS-resident cells. In contrast, we
found CD44 to be clearly expressed by steady-state CNS-resi-
dent leukocytes and further upregulated by microglia and
BAMs during EAE, and by reactive microglia in aging and AD.
Hence, our data suggest that CD44 alone is not a reliable marker
to distinguish CNS-infiltrating cells from CNS-resident cells.
During EAE, wewere able to discriminate subsets of infiltrating
and resident myeloid cells and show that MdCs displayed a
homogeneous macrophage-like phenotype, consistent with
their role in myelin degradation and phagocytosis during EAE
(Spath et al., 2017; Yamasaki et al., 2014). In contrast to high
numbers of MdCs and cDCs, BAM numbers decreased during
EAE, supporting the notion that tissue-resident macrophage
numbers decline with the influx of peripheral inflammatory
monocytes (Davies et al., 2013). At peak disease, BAMs lost their
heterogeneity and almost exclusively co-expressed CD38 and
MHCII. This BAM signature was also seen in geriatric mice to a
lesser extent and may reflect a universal activation profile.
During EAE, microglia became skewed toward an entirely
inflammatory phenotype. This phenotype bore some similar-
ities to the signature in aging and AD-prone mice and may
also in part represent a universal disease-associated microglial
signature, as recently proposed (Krasemann et al., 2017;
Zrzavy et al., 2017). However, EAE microglia also differed
from the age and AD phenotype: EAE microglia dramatically
upregulated MHCII and Sca-1, both IFN-g-responsive genes,
reflecting an interaction of microglia with CNS-invading
T cells. Conversely, they did not upregulate CD14 while age-
and AD-associated microglia did. In addition, the fact that
the entire microglial population in the brain parenchyma
became homogeneously reactive during EAE, compared to a
small subpopulation of responsive microglia during aging and
AD, is likely due to the great amount of cytokines and other
inflammatory mediators delivered to the CNS by invading leu-
kocytes during EAE (Becher et al., 2016, 2017). This also sug-
gests that inflammatory EAE lesions affect microglia across the
entire brain parenchyma even if they accumulate in the spinal
cord, as is the case in EAE. Whereas we assume that microglia
are not pathogenic per se, these global inflammation-induced
changes in microglia may contribute to disease chronification,
neurodegeneration, and brain atrophy, as observed in diseases
like MS. In contrast, during aging and AD, the vast majority of
microglia do not respond, demonstrating that neurodegenera-
tion alone does not lead to the massive immune cell and cyto-
kine influx into the CNS as seen in bona fide inflammatory
diseases such as MS.
Taken together, our atlas identified distinct subsets of BAMs,
steady-state and reactive subsets of microglia, and CNS DC
subsets. We confirmed their identities by reporter and fate map-
ping, ontogeny, and responsiveness to growth factors. Using our
steady-state map to interrogate the same leukocytes during
pathology, we defined robust signatures for BAMs and microglia
Figure 7. BAMs Lose their Heterogeneity during Neuroinflammation but Are Still Distinguishable from MdCs and DCs
(A) CD45+ CNS leukocytes (left) from Cx3cr1CreER Rosa26-RFP and control mice at peak EAE, with quantification (right) of RFP+ cells (n = 2, representative of two
independent experiments).
(B) Total numbers of BAMs, RFP+ BAMs, and MdCs in steady-state and peak EAE Cx3cr1CreER Rosa26-RFP mice.
(C) BAM subset tSNE analysis by mass cytometry between steady-state and peak EAE mice.
(D) Highly upregulated makers between steady-state and peak EAE total BAMs.
(E and F) One-SENSE analysis of lineage and activation profiles of Ly6Chi monocytes, MdCs, and Ly6Clo monocytes (E) and DCs during peak EAE (F).
(G) Expression levels of distinguishing markers between microglia, BAMs, MdCs, and cDCs during peak EAE.
***p value significant (< 0.05) with a BH FDR < 1%. Error bars represent range. See also Figure S7.
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during aging, neurodegeneration, and neuroinflammation. This
atlas can now be used to target and isolate CNS leukocyte sub-
sets with cell-surface protein markers in steady state and their
specific disease-associated forms across pathologic conditions,
thus enabling further studies into the role of these cells in main-
taining CNS homeostasis and in the initiation or resolution of
CNS disease.
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Antibodies
anti-mouse CD45 clone 30-F11, 104-Pd BioLegend Cat # 103102; RRID: AB_312967
anti-mouse CD45 clone 30-F11, 105-Pd BioLegend Cat # 103102; RRID: AB_312967
anti-mouse CD45 clone 30-F11, 106-Pd BioLegend Cat # 103102; RRID: AB_312967
anti-mouse CD45 clone 30-F11, 108-Pd BioLegend Cat # 103102; RRID: AB_312967
anti-mouse CD45 clone 30-F11, 110-Pd BioLegend Cat # 103102; RRID: AB_312967
anti-mouse Ly6G clone 1A8, 141-Pr Fluidigm Cat# 3141008B
anti-mouse Cx3CR1 clone SA011F11, 142-Nd BioLegend Cat# 149002; RRID: AB_2564313
anti-mouse CD88 clone 20/70, 143-Nd BioLegend Cat# 135802; RRID: AB_1953295
anti-mouse CD11a clone M17/4, 144-Nd Bio X Cell Cat# BE0006; RRID: AB_1107578
anti-mouse Siglec-F clone E50-2440, 145-Nd BD Biosciences Cat# 552125; RRID: AB_394340
anti-mouse CD11c clone N418, 146-Nd BioLegend Cat# 117302; RRID: AB_313771
anti-mouse CD45 clone 30-F11, 147-Sm Fluidigm Cat# 3147003B
anti-mouse CD11b clone M1/70, 148-Nd Fluidigm Cat# 3148003B
anti-mouse B220 clone RA3.3A1, 149-Sm Bio X Cell Cat# BE0067; RRID: AB_1107651
anti-mouse Ly6C clone HK1.4, 150-Nd Fluidigm Cat# 3150010B
anti-mouse CD64 clone X54-5/7.1, 151-Eu Fluidigm Cat# 3151012B
anti-mouse CD3 clone 145-2C11, 152-Sm Fluidigm Cat# 3152004B
anti-mouse PDL1 clone 10F.9G2, 153-Eu Bio X Cell Cat# BE0101; RRID: AB_10949073
anti-mouse Ter119 clone TER-119, 154-Sm Fluidigm Cat# 3154005B
anti-mouse CD90 clone T24/31, 155-Gd Bio X Cell Cat# BE0212; RRID: AB_2687698
anti-mouse CD14 clone Sa14-2, 156-Gd Fluidigm Cat# 3156009B
anti-mouse Siglec-H clone 551, 158-Gd BioLegend Cat# 129602; RRID: AB_1227757
anti-mouse Siglec-1 clone 3D6.112, 159-Tb BioLegend Cat# 142402; RRID: AB_10916523
anti-mouse MerTK polyclonal, biotin R&D Systems Cat# BAF591; RRID: AB_2098563
anti-mouse CD135 clone A2F10, 161-Dy eBioscience Cat# 14-1351-82; RRID: AB_467481
anti-mouse CD24 clone J11d, 162-Dy Bio X Cell Cat# BE0227; RRID: AB_2687710
anti-mouse CCR2 clone 475301, APC R&D Systems Cat# FAB5538A; RRID: AB_10645617
anti-mouse F4/80 clone Cl:A3-1, 164-Dy BioRad Cat# MCA497G; RRID: AB_872005
anti-mouse CD38 clone 90, 165-Ho BioLegend Cat# 102702; RRID: AB_312923
anti-mouse CD117 clone 2B8, 166-Er Fluidigm Cat# 3166004B
anti-mouse CD16/32 clone 93, 167-Er BioLegend Cat# 101302; RRID: AB_312801
anti-mouse CD206 clone CO8C2, 168-Er BioLegend Cat# 14170210900233
anti-mouse Sca-1 clone D7, 169-Tm Fluidigm Cat# 3169015B
anti-mouse NK1.1 clone PK136, 170-Er BioLegend Cat# 108702; RRID: AB_313389
anti-mouse/human CD44 clone IM7, 171-Yb Fluidigm Cat# 3171003B
anti-mouse CD86 clone GL-1, 172-Yb Bio X Cell Cat# BE0025; RRID: AB_1107678
anti-mouse CD172 clone P84, 173-Yb BioLegend Cat# 144002; RRID: AB_11203711
anti-mouse MHCII clone M5/114.15.2, 174-Yb Fluidigm Cat# 3174003B
anti-mouse CD43 clone 1B11, 175-Lu BioLegend Cat# 121202; RRID: AB_493382
anti-mouse FcER1a clone MAR-1, 176-Yb BioLegend Cat# 1343021626078
anti-APC clone APC003, 163-Dy BioLegend Cat# 409002; RRID: AB_345357
anti-biotin clone 1D4-C5, 160-Dy BioLegend Cat# 408002; RRID: AB_10642032
anti-GFP clone 1GFP63, 163-Dy BioLegend Cat# 668205; RRID: AB_2616789
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anti-mouse CD38 clone 90, Alexa Fluor 488 BioLegend Cat# 102714; RRID: AB_528796
anti-mouse CD88 clone 20/70, Biotin BioLegend Cat# 135811; RRID: AB_11149683
anti-mouse CD24 clone M1/69, Brilliant Ultra Violet 496 BD Cat# 564664; RRID: AB_2716853
anti-mouse Ly6G clone 1A8, Brilliant Ultra Violet 563 BD Cat# 565707
anti-mouse CD11b clone M1/70, Brilliant Ultra Violet 661 BD Cat# 565080
anti-mouse CD11b clone M1/70, Brilliant Ultra Violet 737 BD Cat# 564443
anti-mouse CD11b clone M1/70, APC BD Cat# 101212; RRID: AB_312795
anti-mouse F4/80 clone BM8, Brilliant Violet 421 BioLegend Cat# 123137; RRID: AB_2563102
anti-mouse F4/80 clone BM8, Brilliant Violet 510 BioLegend Cat# 123135; RRID: AB_2562622
anti-mouse CD206 clone C068C2, Brilliant Violet 605 BioLegend Cat# 141721; RRID: AB_2562340
anti-mouse CD206 clone C068C2, Alexa Fluor 700 BioLegend Cat# 141733; RRID: AB_2629636
anti-mouse Ly6C clone HK1.4, Brilliant Violet 711 BioLegend Cat# 128037; RRID: AB_2562630
anti-mouse Lyve1 clone ALY7, eFlour 660 eBioscience Cat# 50-0443-82; RRID: AB_10597449
anti-mouse CD90.2 clone 30-H12, Brilliant Violet 785 BioLegend Cat# 105331; RRID: AB_2562900
anti-mouse CD90.2 clone 30-H12, Brilliant Violet 605 BioLegend Cat# 105343; RRID: AB_2632889
anti-mouse CD45 clone 30-F11, Brilliant Ultra Violet 395 BD Cat# 564279; RRID: AB_2651134
anti-mouse CD45 clone 30-F11, PE-Cy5 BD Cat# 553082; RRID: AB_394612
anti-mouse CD45 clone 30-F11, Pacific Blue BioLegend Cat# 103126; RRID: AB_493535
anti-mouse CD11c clone N418, PE-Cy5.5 eBioscience Cat# 35-0114-82; RRID: AB_469709
anti-mouse MerTK clone DS5MMER, PE-Cy7 eBioscience Cat# 25-5751-82; RRID: AB_2573466
anti-mouse CX3CR1 clone SA011F11, PE-Dazzle 594 BioLegend Cat# 149013; RRID: AB_2565697
anti-mouse CD44 clone IM7, Brilliant Ultra Violet 737 BD Cat# 564392
anti-mouse CD44 clone IM7, Brilliant Violet 650 BioLegend Cat# 103049; RRID: AB_2562600
anti-mouse CD4 clone RM4-5, Brilliant Violet 650 BioLegend Cat# 100546; RRID: AB_2562098
anti-mouse CD8a clone 53-6.7, Brilliant Ultra Violet 805 BD Cat# 564920; RRID: AB_2716856
anti-mouse CD3 clone 145-2C11, Brilliant Violet 421 BioLegend Cat# 100341; RRID: AB_2562556
anti-mouse CD3 clone 17A2, Alexa Flour 700 eBioscience Cat# 56-0032-82; RRID: AB_529507
anti-mouse CD3 clone 17A2, Brilliant Ultra Violet 737 BD Cat# 564380
anti-mouse CD3 clone 17A2, Brilliant Ultra Violet 395 BD Cat# 740268; RRID: AB_2687927
anti-mouse B220 clone RA3-6B2, APC BioLegend Cat# 103212; RRID: AB_312997
anti-mouse B220 clone RA3-6B2, Brilliant Violet 785 BioLegend Cat# 103205; RRID: AB_312990
anti-mouse MHCII clone M5/114.15.2, Alexa Flour 700 BioLegend Cat# 107622; RRID: AB_493727
anti-mouse MHCII clone M5/114.15.2, Pacific blue BioLegend Cat# 107620; RRID: AB_493527
anti-mouse MHCII clone M5/114.15.2, Brilliant Blue 700 BD Cat# 746197
anti-mouse Siglec-H clone 551, PE eBioscience Cat# 12-0333-82; RRID: AB_10597139
anti-mouse NK1.1 clone PK136, PE BD Cat# 553165; RRID: AB_394677
rat IgG2bk isotype control clone rtk4530, Pacific blue BioLegend Cat# 400627; RRID: AB_493561
Streptavidin polyclonal, Brilliant Ultra Violet 661 BD Cat# 565081
Streptavidin polyclonal, PE-Cy5 BD Cat# 554062; RRID: AB_10053563
anti-mouse Iba1 clone 019-19741 Wako Cat# 019-19741; RRID: AB_839504
anti-mouse MHCII clone M5/114.15.2, Alexa Fluor 488 Biolegend Cat# 107616; RRID: AB_493523
anti-mouse CD206 clone MR5D3, Biotin Bio-Rad Cat# MCA2235BT; RRID: AB_1101315
anti-mouse CD11c clone N418, APC BioLegend Cat# 117310; RRID: AB_313779
anti-mouse Collagen IV polyclonal Bio-Rad Cat# 2150-1470; RRID: AB_2082660
goat anti-rabbit polyclonal, Alexa Fluor 546 Thermo Fisher Cat# A11010; RRID: AB_2534077
goat anti-rabbit polyclonal, Alexa Fluor 488 Thermo Fisher Cat# A11034; RRID: AB_2576217
goat anti-rat polyclonal, Alexa Fluor 647 Thermo Fisher Cat# A21247; RRID: AB_141778
goat anti-rat polyclonal, Alexa Fluor 488 Thermo Fisher Cat# A11006; RRID: AB_2534074
goat anti-rat polyclonal, Cy3 Life Technologies Cat# A11034; RRID: AB_2576217
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for reagents should be directed to and will be fulfilled by Lead Contact Burkhard Becher (becher@
immunology.uzh.ch).
EXPERIMENTAL MODEL DETAILS
C57BL/6 (wild-type) mice were purchased from Janvier Laboraories and were taken to adulthood at 8 weeks of age or to geriatric
age at 1.5 years of age and tissues were harvested together. Sall-1GFP reporter mice were described previously (Yuri et al.,
2009). Cx3cr1CreER Rosa26-RFP fatemap mice were kindly provided by S. Jung (Weizmann Institute of Science) (Yona et al.,
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
goat anti-hamster polyclonal, Alexa Fluor 546 Thermo Fisher Cat# A21111; RRID: AB_2535760
donkey anti-rabbit polyclonal, Alexa Fluor 555 Jackson Cat# 712-165-153; RRID: AB_2340667
Streptavidin polyclonal, Alexa Fluor 488 Thermo Fisher Cat# S112223; RRID: AB_2336881
Streptavidin polyclonal, Alexa Fluor 647 Thermo Fisher Cat# S32357; RRID: AB_2336066
anti-mouse Ly6G clone 1A8, purified BioLegend Cat# 127602; RRID: AB_1089180
Chemicals, Peptides, and Recombinant Proteins
vWF Abcam Cat# ab6994; RRID: AB_305689
DAPI Life Technologies Cat# D3571; RRID: AB_2307445
FLt3L Bio X Cell Cat # BE0098; RRID: AB_10949072
anti-CSF1R clone AFS98 Bio X Cell Cat# BE0213; RRID: AB_2687699
Zombie NIR dye Biolegend Cat# 423106
Iridium Sigma Cat# 520721
Cisplatin Sigma Cat# P4394
MAXPAR Fix/Perm buffer Fluidigm Cat# 201067
MAXPAR water Fluidigm Cat# 201069
USEDECALC solution MEDITE Cat# 40-3310-00
Perm wash Home-made N/A
Palladium 104, 105, 106, 108, 110 Trace N/A
Metal labeling kits Fluidigm N/A
normal goat serum Life Technologies Cat# PCN500
PBS Homemade N/A
Percoll GE Cat# P4937
Deposited Data
CyTOF data from C57BL/6 mice This paper https://community.cytobank.org/
cytobank/experiments/69323
CyTOF data from APP/PS1 mice and littermate controls This paper https://community.cytobank.org/
cytobank/experiments/69324
Software and Algorithms
FlowJo v10.2 Tree Star https://www.flowjo.com/
Cytobank Kotecha et al., 2010 https://www.cytobank.org/
MATLAB R2016a N/A https://www.mathworks.com/
Normalizer Finck et al., 2013 https://github.com/nolanlab/bead-
normalization/releases
t-SNE Van Der Maaten and Hinton, 2008 https://github.com/jkrijthe/Rtsne
FlowSOM Van Gassen et al., 2015 https://github.com/SofieVG/FlowSOM
Scaffold Spitzer et al., 2015 https://github.com/nolanlab/scaffold
One-SENSE Cheng et al., 2016 N/A
R R Development Core Team, 2008 https://www.r-project.org/
R Studio N/A https://www.rstudio.com/
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2013). Heterozygous APP/PS1 mice which overexpress the familial AD mutant form of human APP (the Swedish mutation, K670N/
M671L) and PS1 (M146L/L286V) transgenes under the transcriptional control of the neuron-specific mouse Thy-1 promoter (Radde
et al., 2006), and littermate controls, aged 4 months were kindly provided by F. Heppner (Charite´–Universit€atsmedizin Berlin). All an-
imal experiments performed in this study were approved by the Cantonal Veterinary Office Zurich.
METHOD DETAILS
In vivo treatments and EAE induction
Anti-CSF1R (clone AFS98) was administered by intraperitoneal (i.p.) injection on day 0 (2 mg) and day 2 (1 mg), diluted in PBS, and
mice were euthanized on day 9. A 10 mg dose of Flt3L was administered i.p. daily for 9 days, after which mice were euthanized.
Tamoxifen (Sigma) was dissolved in ethanol and corn oil to 25 mg/ml and administered in 200 mL doses via oral gavage (5 mg/dose)
to Cx3cr1CreER Rosa26-RFP mice every second day for 8-10 days. After 5 weeks mice were either euthanized or immunized for EAE
induction: Cx3cr1CreER Rosa26-RFP mice (5 weeks after tamoxifen administration) or C57BL/6 mice (aged 8 weeks) were injected
with MOG35-55 peptide emulsified in Complete Freund’s Adjuvant sub-cutaneously (s.c.) and Pertussis toxin i.p., and scored, as
previously described (Mrdjen et al., 2017). Peak of disease was defined when mice reached a score of 3-4 at approximately
14 days after immunization.
Tissue harvesting and cell preparation
Mice were sacrificed by injection of pentobarbital (50 mL at 300 mg/ml) i.p. and transcardiac perfusion was performed with PBS and
heparin (5 u/ml). The CNS was harvested and the dura mater was removed from the skull and included in the sample. The complete
CNS samples (including meninges and choroid plexus) were processed into single cells as previously described (Mrdjen et al., 2017):
briefly, the CNS was cut into small pieces in an eppendorf tube and incubated with digestion buffer (RPMI supplemented with 2%
FBS, 2mMHEPES, 0.4mg/ml Collagenase D and 2mg/ml DNase) for 30minutes at 37C, shaking. Enzymatic digestion was stopped
with EDTA (5 mM), the sample was homogenized with a syringe and the homogenate was filtered through a 70 mm cell strainer. This
was followed by gradient centrifugation with 30% Percoll (GE Healthcare Life Sciences) in PBS (v/v) (23’500 x g for 30 minutes at 4C
without brakes), removal of myelin with a suction pump and filtration to generate a single-cell suspension. The samples were then
ready for staining with mass- or fluorescence cytometry antibodies.
Mass cytometry
Mass cytometry antibodies were either labeled in-house using antibody-labeling kits and protocols purchased from Fluidigm. Anti-
bodies were individually titrated and optimized as into the final panel prior to use, ensuring that each parameter was informative. We
used 5 palladiummetal isotopes for live cell barcoding of samples with CD45 (Mei et al., 2015), while keeping CD45-147Smas a com-
mon channel to clearly identify cells expressing varying degrees of CD45, such as microglia, as previously described (Mrdjen et al.,
2017). Briefly, individual samples from steady-state adult, steady-state geriatric and peak EAE adult C57BL/6 mice were incubated
with respective CD45-Pd + CD45-147 Sm antibodies in PBS for 30 minutes at 37C after which they were washed twice with FACS
buffer (PBS supplemented with 0.5% BSA), then combined into composite samples. In another experiment, the forebrain and hind-
brain were taken from 4-month-old APP/PS1 or littermate control mice, barcoded separately, and combined into composite sam-
ples.We used one barcoding CD45-Pd per group in combination with CD45-147 Sm in order to avoid epitope saturation andmaintain
signal intensity, and were therefore able to barcode 5 samples from separate groups per composite sample. This was followed by
incubation of the composite samples with the cocktail of primary panel antibodies (Table S1) for 30 minutes at 37C, washing with
FACS buffer and then incubating with secondary antibodies for 20 minutes at 4C. After washing, samples were incubated with in-
tercalating solution (Iridium (Sigma) in MaxPar Fix/Perm buffer (Fluidigm)) overnight at 4C. Prior to acquisition, the samples were
washed twice with FACS buffer and oncewithMilliQ water. Barcoded composite samples were acquired on aHelios mass cytometer
(Fluidigm). Quality control and tuning processes on the Helios were performed on a daily basis before acquisition. Data from different
days and across acquisition time was normalized by adding five-element beads to the sample immediately before acquisition and
using the MATLAB-based normalization software, as described previously (Finck et al., 2013).
Fluorescence cytometry
Samples were incubated with primary antibodies in PBS for 30 min at 4C, washed with PBS and incubated with secondary
antibodies for 20 min at 4C. After washing, cells were fixed and permeabilized with 100 mL BD Cytofix/Cytoperm (containing
4.2% Formaldehyde) for 20 min at 4C, and washed with Perm buffer (PBS with 0.1% saponin) before intracellular labeling
which was performed for CD3, CD4 and CD8 in Perm buffer for 30 min at 4C, with final washing in Perm buffer. Samples
were resuspended in PBS and analyzed by flow cytometry with a FACSymphony cell analyzer. Before acquisition, PMT voltages
were adjusted manually in order to reduce fluorescence spillover, and single-stain controls were acquired for compensation matrix
calculation.
Immunity 48, 380–395.e1–e6, February 20, 2018 e4
Tracking intra-vascular cells in the CNS
In order to label intra-vascular cells within the steady state CNS we injected PE conjugated anti-CD45 (7.5 mg in PBS) i.v. into adult
C57BL/6 mice and euthanized them after 3 minutes, performed transcardiac perfusion and harvested the CNS, as previously
described (Anderson et al., 2014). Single cell suspensions were then stained with fluorescence cytometry antibodies.
Immunohistochemistry for BAMs
C57BL/6 mice were transcardially perfused with PBS and heparin (5u/ml) followed by 2%–4% (wt/vol) paraformaldehyde (PFA) in
0.1 M phosphate buffer (pH 7.4). The CNS, excluding the dura mater, was further fixed for 6-12 hours at 4C and rinsed with PBS
followed by cryoprotection with 30% (wt/vol) sucrose in PBS. Samples were embedded in OCT (Medite). Cryo-sectioning was
performed with a thickness of 12-30mm using a Hyrax C60 cryostat (Zeiss). The dura mater was fixed for 2-4 hours at 4C followed
by removal from the skull, direct placing onto superfrost plus slides (Thermo Scientific) and storage at 20C. For quantification of
BAM, subsets the choroid plexus was removed from the CNS after fixation and also directly placed onto slides. CNS tissue sections,
dura mater and choroid plexus mounts were permeabilized by incubation in blocking solution (PBS supplemented with 0.2% Triton
X-100 and 5% normal goat serum) for 1 hour at room temperature. Sections and tissues on slides were labeled primary antibodies
either at 4C, over night or at room temperature for 2 hours, and free-floating sections for 24-72 hours at 4C in staining solution (PBS
supplemented with 0.1% Triton X-100 and 2% normal goat serum): anti-Iba1 (1:500), anti-MHCII (1:200), anti-Lyve1 (1:200), anti-
CD206 (1:100) and anti-CD11c (1:40). After washing, samples were incubated either at 4C overnight or for 1-2 hours at room tem-
perature with the respective secondary antibodies (anti-rabbit, anti-rat, streptavidin, etc., 1:500-700). Washing was repeated and
sections were mounted with 1 drop of IS mounting medium with DAPI (Dianova) or SlowFade Gold antifade reagent with DAPI (In-
vitrogen). Fluorescence photomicrographs were acquired on a Vectra3 (Perkin Elmer) fluorescencemicroscope using a x20 objective
lens. Filters for AF488, AF546, AF647, AF 660 and DAPI were used for imaging tissues to facilitate subsequent unmixing of all colors
according to their respective spectra.
Immunohistochemistry for neutrophils
Mice were transcardially perfused using 4% (wt/vol) PFA. The fur was removed and heads (including the skull and brain) were
transferred into USEDECALC solution for 6 days (MEDITE Cancer Diagnostics, USA) and decalcified using ultrasonic decalcifying
automate USE 33 (MediteGmbH, Switzerland). Specimenswere subsequently sectioned into 3 mmslices and embedded in paraffin
for further histological processing. Antigen retrieval was performed on sections by microwave heating at 98C for 15 min (microMED
T/T Mega, Hacker-Milestone) in citrate buffer (0.01M citric acid, pH6).
For brightfield immunostaining, endogenous peroxidases were neutralized by incubation in PBS supplemented with 3%H2O2, and
non-specific binding blocked using PBS supplemented with 10%FCS. Tissue sections were incubated with unconjugated anti-Ly6G
(1:1000). Bound primary antibody was visualized with biotin-labeled anti–rat antibody and streptavidin-peroxidase staining method
using polymerized 3,30-diaminobenzidine (all reagents from Dako; Haemalaun counterstaining of nuclei).
For immunofluorescence staining, non-specific binding was also blocked using PBS supplemented with 10% FCS. Sections were
subsequently incubated with unconjugated anti-Ly6G (1:500) and with rabbit anti-vWF antibody (1:1000). Bound antibodies were
visualized with AF555–labeled donkey anti–rabbit (1:200) and Cy3-labeled goat anti–rat (1:200) secondary antibodies. Nuclei
were stained with DAPI (1:5000). All antibodies were diluted in DAKO Real Antibody Diluent.
QUANTIFICATION AND STATISTICAL ANALYSIS
Pre-processing of mass and flow cytometry data
For mass cytometry data live cells were exported by manual gating on Event_length, DNA (191Ir and 193Ir), and live cells (195Pt)
using FlowJo software (Tree Star), as previously described (Mrdjen et al., 2017). Next, cells were assigned to their initial samples
using Boolean gating in FlowJo. Background subtracted.fcs files were exported from FlowJo, imported into the R environment
and transformed using an inverse hyperbolic sine (arcsinh) function with a cofactor of 5 (Bendall et al., 2011). For flow cytometry
data, after compensation correction in FlowJo, live, single, background subtracted and compensated cells were exported bymanual
gating. Samples were not barcoded so debarcoding was not necessary. The appropriate transformation cofactors were determined
by uploading the files into Cytobank (https://www.cytobank.org) (Kotecha et al., 2010) and using the Scales feature; thereafter trans-
formation was carried out in MATLAB and transformed files were imported into the R environment for further pre-processing and
analysis. To equalize the contribution of each marker in subsequent automated data analysis steps of mass and flow cytometry
data, we performed percentile normalization (Levine et al., 2015), normalizing all data to the 99.9th – 99.99th percentile of the merged
sample in each experiment, depending on the number of outliers present. This preserves inter-sample variability in maximum expres-
sion values, whichmight be biologically relevant, and normalizes inter-markermaximumexpression values, whilemaintaining original
staining indices.
Automated population identification in high-dimensional data analysis
Pre-processing of the raw data was followed by dimensionality reduction and visualization by t-Distributed Stochastic Neighbor
Embedding (t-SNE) (Mair et al., 2016; Van Der Maaten and Hinton, 2008) with parameters as listed in the figure legends, clustering
with FlowSOM into initial 100 nodes (VanGassen et al., 2015), followed by expert-guidedmanual metaclustering using the t-SNEwith
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overlaid marker expression values and a heatmap of median expression values of the initial automated 100 FlowSOM nodes (Hart-
mann et al., 2016). In some cases, major cell populations were separated for further clustering into subsets. When comparing
different groups, for example steady state and EAE samples, the t-SNE and clustering analyses were performed on the combined
datasets. Force- and landmark- directed maps were generated with a modified version of the Scaffold application (Spitzer et al.,
2015), and landmark populations that were manually gated in FlowJo and exported. We used the 100 initial FlowSOM nodes as
unsupervised Scaffold clusters instead of the built-in clustering algorithm of the Scaffold application. This allowed the validation
of expert-guided manual metaclustering by the grouping of FlowSOM nodes around manually-gated landmark nodes in the Scaffold
map. Categorical ONE-Sense analysis was performed in the R environment by generating a one-dimensional t-SNE axis using line-
age or activation markers, and a progressive lineage or activation heatmap along each axis, which were then arranged side-by-side.
Statistics were calculated using Student’s t test and the Benjamini-Hochberg post-test for false discovery rates (FDR). Stars
were assigned according to the FDR: * = significant (i.e., p value < 0.05) with a FDR of 10%, ** = significant with a FDR of 5% and
*** = significant with a FDR of 1%. The n number indicates the number of mice used in each experiment.
Quantification of cells from immunohistochemistry
Semi-automated cell detection and quantification of BAM subsets was performed using the implemented Inform Software (Perkin
Elmer). A minimum of 5 sections per compartment (dura mater, pia mater, perivascular space, choroid plexus), per mouse were
analyzed and a minimum of 4 regions of interest per section. Images used for analyses were taken on the SP8 upright (Leica) with
a 20 3 emulsion objective at 1024 3 1024 pixels in xy. A pinhole size of 60 mm was used. Images were taken in frames with a line
average of 16. DAPI and AF546 were detected in one sequence and AF488 and AF647 were detected in a second sequence.
Alternatively, images were taken sequentially with a SP5 Leica confocal laser scanning microscope (Leica) equipped with argon
and helium lasers and the 40 3 (oil immersion, NA1.25) objective. Images were processed and merged by Imaris Imaging software
(Bitplane).
DATA AND SOFTWARE AVAILABILITY
Mass cytometry data of CNS leukocytes from C57BL/6 adult, geriatric and EAE mice (https://community.cytobank.org/cytobank/
experiments/69323) as well as from 4-month-old APP/PS1 and littermate control mice (https://community.cytobank.org/
cytobank/experiments/69324) are available online.
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